Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 6 of 6 for “"t-dm1"”.
-
A NOVEL, RAS-INDEPENDENT ROLE FOR NF1 IN MICROTUBULE DYNAMICS AND DAMAGE REPAIR DICTATES SENSITIVITY TO T-DM1 IN HER2 POSITIVE BREAST CANCER.
… show that NF1 loss sensitizes cancer cells to T-DM1, the first approved Antibody-drug conjugate (ADC) in breast cancer, through a novel, RAS-independent function on microtubular dynamics and repair. NF1 exhibits all biochemical properties of a bona fide MAP and specifically enhances intratubular …
-
ANTIBODY-DRUG CONJUGATES FOR THE TREATMENT OF BREAST CANCER.
… deruxtecan (T-DXd) and trastuzumab emtansine (T-DM1) are anti-HER2 antibody-drug conjugates (ADCs) which have shown robust efficacy for treating breast cancer. For both ADCs, however, we lack effective biomarkers to predict outcomes from pre-treatment samples. Methods: To unveil predictive …
-
Development and Evaluation of Novel Anti-HER2 Theranostics Against HER2-Positive Breast Cancer
… therapies, such as pertuzumab, margetuximab, T-DM1, T-DXd, lapatinib, neratinib, pyrotinib, gefitinib, and tucatinib, have been developed. Nonetheless, despite of their improved effectiveness, de novo and acquired resistance to current treatments are very common in BC patients; almost all …
-
NF1 AS A REGULATOR OF CYTOSKELETON DYNAMICS AND BIOMARKER FOR DECISION-MAKING IN HER2-POSITIVE BREAST CANCER
… conjugate (ADC) trastuzumab emtansine (T-DM1). This hypersensitivity was specific to the mertansine MT-targeting component (DM1) since it was i) replicated by the naked payload but not the antibody alone; ii) absent with other ADCs (i.e.: trastuzumab deruxtecan [T-DXd]); iii) not …
-
Enhertu (Trastuzumab Deruxtecan): Ανασκόπηση της κλινικής ανάπτυξης σε ασθενείς με HER2+ καρκίνο μαστού / Enhertu (Trastuzumab Deruxtecan): A review of clinical development in patients with HER2-positive breast cancer
… κλινική δοκιμή που συγκρίνει την T-DXd με την T-DM1, καθιέρωσε την T-DXd ως θεραπεία εκλογής δεύτερης γραμμής, με λόγο κινδύνου (HR) για PFS 0,28 και σημαντική βελτίωση στη συνολική επιβίωση. Η DESTINY-Breast02 επιβεβαίωσε το όφελος μετά από θεραπεία με T-DM1, ενώ αναλύσεις υποομάδων ανέδειξαν …
-
Quantitative analysis of cellular processing of Antibody-Drug Conjugates
… this model using a clinically approved ADC, T-DM1. Sensitivity analysis suggests that the amount of drug that is delivered to cells is a function of the amount of drug that comes in via internalization and the amount the leaves via drug efflux. This work also demonstrates how it is important to …